Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun finally shines on Horizant, as FDA OK’s GSK-XenoPort RLS drug

This article was originally published in Scrip

Executive Summary

Investors jumped for joy on 7 April on the news that GlaxoSmithKline and its partner XenoPort finally gained the US FDA's blessing for their extended-release gabapentin enacarbil product Horizant (XP13512/GSK1838262) as a treatment for adults with moderate-to-severe primary restless legs syndrome (RLS) – an approval that came after a long and winding road.


Related Content

Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts